Cardeas Pharma Obtains $3,500,000 Series B Funding

  • Feed Type
  • Date
  • Company Name
    Cardeas Pharma
  • Mailing Address
    2025 First Avenue Seattle, WA 98121 USA
  • Company Description
    Cardeas Pharma is developing a novel antibiotic formulation of two drugs with synergistic activity against all relevant, highly resistant Gram-negative bacilli, including Pseudomonas aeruginosa, Acinetobacter baumannii, and carbapenem-resistant Enterobacteriaceae.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
  • M&A Terms
  • Venture Investor

Trending on Xconomy